Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DM‐INSULIN</scp> randomized trial

A. Leiter, Lawrence; Cariou, Bertrand; Müller‐Wieland, Dirk; M. Colhoun, Helen; Del Prato, Stefano; J. Tinahones, Francisco; K. Ray, Kausik; Bujas‐Bobanovic, Maja; Domenger, Catherine; Mandel, Jonas; Samuel, Rita; R. Henry, Robert

doi:10.1111/dom.13114

Public

Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial

Published in Diabetes Obesity and Metabolism • Sep 14, 2017

Authors:

Lawrence A. Leiter

Bertrand Cariou

Dirk Müller‐Wieland

Abstract

AIMS: To investigate the efficacy and safety of alirocumab in participants with type 2 (T2D) or type 1 diabetes (T1D) treated with insulin who have elevated LDL cholesterol levels despite maximally tolerated statin therapy. METHODS: Participants at high cardiovascular risk with T2D (n = 441) or T1D ...

Subject

Alirocumab

Medicine

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!